Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: A remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD)

Eugenia Giraldi, Massimo Provenzi, Roberto Fiocchi, Michele Colledan, Pieremilio Cornelli, Giuliano Torre, Alessandro Rambaldi, Valentino Conter

Research output: Contribution to journalArticlepeer-review

Abstract

Management of aggressive, usually late-occurring, post-transplant lymphoproliferative disorders (PTLDs), a life-threatening complication after solid organ transplants, remains controversial. Four children affected by aggressive CD20+ PTLDs received a chemo-immunotherapy regimen for remission induction based on fludarabine, cyclophosphamide, doxorubicin, and rituximab, associated with a rapid discontinuation of immunosuppression (IS). Subsequent consolidation chemotherapy consisted of Berlin-Frankfurt-Münster-modified blocks. All patients achieved a complete remission, which persisted for 25, 68+, 80+, and 103+ months after diagnosis. Therapy was well tolerated. No patients developed allograft rejection during PTLD treatment. Our experience suggests that this chemo-immunotherapeutic approach may be an effective treatment strategy while allowing for a concomitant discontinuation of IS.

Original languageEnglish
Pages (from-to)324-328
Number of pages5
JournalPediatric Blood and Cancer
Volume57
Issue number2
DOIs
Publication statusPublished - Aug 2011

Keywords

  • Children
  • Fludarabine-based therapy
  • PTLD
  • Rituximab
  • Solid organ transplantation
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Fingerprint Dive into the research topics of 'Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: A remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD)'. Together they form a unique fingerprint.

Cite this